{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:09:49Z","timestamp":1790690989172,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Densitometry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jocd.2026.101747","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T15:09:38Z","timestamp":1789571378000},"page":"101747","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Combined baseline P1NP and TRAcP5b classification predicts differential bone mineral density response to romosozumab: A retrospective cohort study of 287 postmenopausal women"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-2849-6577","authenticated-orcid":false,"given":"Ryo","family":"Nakano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumi","family":"Ichisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenya","family":"Saruta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Kogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jocd.2026.101747_bib0001","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocd.2026.101747_bib0002","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocd.2026.101747_bib0003","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocd.2026.101747_bib0004","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/jbmr.3622","article-title":"One year of romosozumab followed by two years of denosumab maintains fracture risk reductions","volume":"34","author":"Lewiecki","year":"2019","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2026.101747_bib0005","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","article-title":"Romosozumab versus teriparatide in postmenopausal women transitioning from bisphosphonate therapy","volume":"390","author":"Langdahl","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jocd.2026.101747_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2021.105219","article-title":"Effects of prior osteoporosis treatment on romosozumab response","volume":"88","author":"Ebina","year":"2021","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jocd.2026.101747_bib0007","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S2213-8587(17)30184-5","article-title":"Use of bone turnover markers in postmenopausal osteoporosis","volume":"5","author":"Eastell","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jocd.2026.101747_bib0008","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00198-010-1501-1","article-title":"Markers of bone turnover for prediction of fracture risk and monitoring of osteoporosis treatment","volume":"22","author":"Vasikaran","year":"2011","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2026.101747_bib0009","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40364-017-0097-4","article-title":"Bone biomarkers for the clinical assessment of osteoporosis: recent developments and future perspectives","volume":"5","author":"Kuo","year":"2017","journal-title":"Biomark Res"},{"key":"10.1016\/j.jocd.2026.101747_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00774-012-0392-y","article-title":"Guidelines for the use of bone metabolic markers in diagnosis and treatment of osteoporosis","volume":"31","author":"Nishizawa","year":"2013","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.jocd.2026.101747_bib0011","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.cca.2019.08.012","article-title":"Executive summary of the Japan Osteoporosis Society guide for the use of bone turnover markers in the diagnosis and treatment of osteoporosis (2018 Edition)","volume":"498","author":"Nishizawa","year":"2019","journal-title":"Clin Chim Acta"},{"issue":"6","key":"10.1016\/j.jocd.2026.101747_bib0012","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1007\/s00774-013-0460-y","article-title":"Study of the distribution by age group of serum cross-linked C-terminal telopeptide of type I collagen and procollagen type I N-propeptide in healthy Japanese women to establish reference values","volume":"31","author":"Nomura","year":"2013","journal-title":"J Bone Miner Metab"},{"issue":"Suppl 6","key":"10.1016\/j.jocd.2026.101747_bib0013","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1007\/s001980070004","article-title":"Pre-analytical variability of biochemical markers of bone turnover","volume":"11","author":"Hannon","year":"2000","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2026.101747_bib0014","first-page":"1461","article-title":"Identification of P1NP as a predictor of treatment nonresponse to romosozumab","volume":"32","author":"Wada","year":"2021","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2026.101747_bib0015","first-page":"305","article-title":"Comparison of romosozumab in treatment-naive and bisphosphonate-pretreated patients","volume":"112","author":"Ebina","year":"2023","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.jocd.2026.101747_bib0016","first-page":"1174","article-title":"Use of CTX-I and P1NP as bone turnover markers: national bone health alliance recommendations","volume":"102","author":"Szulc","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jocd.2026.101747_bib0017","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1359\/jbmr.2000.15.4.613","article-title":"Suppressed bone turnover by bisphosphonates increases microdamage accumulation","volume":"15","author":"Mashiba","year":"2000","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2026.101747_bib0018","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00774-013-0447-8","article-title":"Diagnostic criteria for primary osteoporosis: year 2012 revision","volume":"31","author":"Soen","year":"2013","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.jocd.2026.101747_bib0019","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/jbmr.3051","article-title":"Treatment sequence matters: anabolic and antiresorptive therapies for osteoporosis","volume":"32","author":"Cosman","year":"2017","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2026.101747_bib0020","first-page":"2331","article-title":"Effects of teriparatide and denosumab alone and combined in women with postmenopausal osteoporosis: the DATA extension study","volume":"34","author":"Tsai","year":"2019","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2026.101747_bib0021","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1210\/jc.2004-0952","article-title":"Severely suppressed bone turnover: a potential complication of alendronate therapy","volume":"90","author":"Odvina","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jocd.2026.101747_bib0022","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1359\/jbmr.081206","article-title":"Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model","volume":"24","author":"Li","year":"2009","journal-title":"J Bone Miner Res"}],"container-title":["Journal of Clinical Densitometry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094695026000818?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094695026000818?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:52:10Z","timestamp":1790689930000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094695026000818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1094695026000818"],"URL":"https:\/\/doi.org\/10.1016\/j.jocd.2026.101747","relation":{},"ISSN":["1094-6950"],"issn-type":[{"value":"1094-6950","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combined baseline P1NP and TRAcP5b classification predicts differential bone mineral density response to romosozumab: A retrospective cohort study of 287 postmenopausal women","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Densitometry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocd.2026.101747","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The International Society for Clinical Densitometry. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101747"}}